Abstract
In 2007, blood diseases cost the US' s economy $114bn. In 2004, a reported
232,000 deaths in the US were due to anaemia, myeloproliferative and
myelodysplastic disorders, bleeding disorders, white blood cell disorders and
thrombosis collectively. From oxygen delivery to immunological defence to
clotting, blood has vital physiological functions, and clear, expensive
treatments. This brand new blood diseases treatments report breaks down
therapies into four main groups:
- Antithrombotics
- Anti-anaemics
- Clotting Factors
- Others
In 2006 visiongain valued this market at $37406m, But do you know how the
blood diseases treatments market will fare 5, 10 and 15 years from now? Will
it increase in sales and bring in significant profits or will it be rocked by
widespread patent expiration and ensuing generic competition? This report
provides these answers, with detailed quantitative and qualitative analysis.
This is information every player in the blood diseases treatments market
should not be without.
Visiongain' s new Blood Disorders 2008 report covers:
- An in-depth analysis of the major blood diseases and treatments
- Discussion of most effective innovative treatments for blood diseases
- Trends in the overall world blood diseases treatments market, with
detailed market forecasts from 2008 to 2023
- Reasons behind the trends
- A breakdown of the world market into the principal market segments, with
forecasts and predictions of future market share values
- Sales forecasts of the leading drugs in each sub-market
- A SWOT analysis of the blood disorders market
- Discussion of relevant market drivers and restraints
- A geographical breakdown of relevant global sales trends into the leading
national markets
- Pipeline developments in blood disorders
This study was achieved through research of relevant news, company reports,
expert opinion, academic literature and gold-standard IMS databases. Financial
forecasting based upon in-depth research was performed, with accompanying SWOT
analyses. The result is a comprehensive market-based study with extensive
analysis and informed opinion.
Why You Should Buy This Report
This 115+ page report features over 25 tables, 50 graphs, market forecasts,
current news, detailed insight, the latest developments, all with up-to-date
analysis and informed opinion. This visiongain report is a vital aid to your
gaining an understanding of this important market sector, giving your company
' the edge' on its competitors.
Importantly report gives answers to relevant questions such as:
- How will sales for blood disorder treatments change from 2006-2013 and
beyond?
- What is the market share of the four classes of treatments and how will
they change in the years ahead?
- What are the top ten drugs in the blood diseases treatments market
currently - how will they fare from now until 2013?
- Which group of treatments will contract the most over the next five years?
- Which drugs dominate each treatment group, present and future?
- What are the main issues facing the market worldwide, both present and up
to 2023?
- Where will the main opportunities lie from now onwards?
- Will the US continue to dominate the blood diseases treatments market?
Where do the other leading pharmaceutical nations stand?
- In which stages of development are relevant pipeline products and what are
their prospects?
Other benefits to you when you order this report:
- - Full searchable report when you buy the company or corporate editions
- - Copies can be easily printed for offline reading
Table of Contents
Chapter 1: Executive Summary
Chapter 2: Blood Diseases and their Treatments
- 2.1 Functions of Blood
- 2.1.1 Haemopoiesis
- 2.1.2 Haemostasis
- 2.2 Anaemia
- 2.2.1 Iron Deficiency
- 2.2.2 Anaemia of Chronic Disease
- 2.2.3 Megaloblastic Anaemia
- 2.2.4 Pernicious Anaemia
- 2.2.5 Aplastic Anaemia
- 2.2.6 Haemolytic Anaemia
- 2.2.6.1 Inherited Haemolytic Anaemia: Hereditary Spherocytosis,
Hereditary Elliptocytosis, Thalassaemia, Sickle Cell Disease and
Glucose-6-phosphate Deficiency
- 2.2.6.2 Acquired Haemolytic Anaemia: Autoimmune Haemolytic Anaemia and
Non-immune Haemolytic Anaemia
- 2.2.7 Anaemia and Aging
- 2.3 Myeloproliferative and Myelodysplastic Disorders
- 2.3.1 Polycythaemia: Polycythaemia Vera and Secondary Polycythaemia
- 2.3.2 Primary Thrombocythaemia
- 2.3.3 Primary Myelofibrosis (Myelosclerosis)
- 2.4 Bleeding Disorders
- 2.4.1 Autoimmune Thrombocytopenic Purpura
- 2.4.2 Inherited Coagulation Disorders
- 2.4.2.1 Haemophilia A
- 2.4.2.2 Haemophilia B
- 2.4.2.3 Von Willebrand' s Disease
- 2.4.3 Acquired Coagulation Disorders
- 2.4.3.1 Disseminated Intravascular Coagulation
- 2.5 White Blood Cell Disorders
- 2.6 Thrombosis
- 2.6.1 Arterial Thrombosis
- 2.6.2 Venous Thrombosis
Chapter 3: Blood Diseases Treatments
- 3.1 Antithrombotic Treatments
- 3.1.1 Platelet Aggregation Inhibitors
- 3.1.2 Anticoagulants Injectable
- 3.1.3 Anticoagulants Non-injectable
- 3.1.4 Fibrinolytics
- 3.1.5 Direct Thrombin Inhibitors
- 3.1.6 Antithrombin III and Other Protease Inhibitors
- 3.1.7 Other Antithrombotic Treatments
- 3.2 Anti-anaemic Treatments
- 3.2.1 Erythropoietin Products
- 3.2.2 Iron Replacement Therapy
- 3.2.3 Other Anti-anaemic Treatments
- 3.3 Clotting Factors
- 3.4 Other Treatments
Chapter 4: Blood Diseases Treatments World Market
- 4.1 Market Analysis
- 4.2 Market Shares
- 4.3 Top Ten Drugs
- 4.4 Percentage Change 2006-2013
Chapter 5: Antithrombotics Market
- 5.1 Market Analysis
- 5.2 The Platelet Aggregation Inhibitors Dominate the Antithrombotics Market
- 5.3 Drugs Generating below $300m dominate the Antithrombotics Market
- 5.4 Platelet Aggregation Inhibitors Market
- 5.5 Plavix Dominates the Platelet Aggregation Inhibitors Market
- 5.6 Plavix
- 5.6.1 Threat to Plavix' s Sales in 2006
- 5.6.2 Plavix' s Competitors
- 5.6.3 Plavix' s Loss of Patent Protection
- 5.7 Clopidogrel Aptx' s Withdrawal
- 5.8 Pletaal
- 5.8.1 Pletaal' s Indications
- 5.8.2 Potential Market Expansion for Pletaal
- 5.9 Integrilin
- 5.9.1 The Leading Glycoprotein IIb/IIIa Receptor Inhibitor
- 5.9.2 Integrilin' s Competitors
- 5.9.3 Potential Market Expansion for Integrilin
- 5.10 Injectable Anticoagulants Market
- 5.11 Lovenox Dominates the Injectable Anticoagulants Market
- 5.12 Lovenox
- 5.12.1 A Leading Low Molecular Weight Heparin
- 5.12.2 Lovenox' s Loss of Patent Protection in 2012
- 5.12.3 Potential Market Expansion for Lovenox
- 5.12.4 Lovenox' s Competitors
- 5.13 Fraxiparine
- 5.14 Fragmin
- 5.15 Other Anti-thrombotics
Chapter 6: Anti-anaemics World Market
- 6.1 Market Analysis
- 6.2 Erythropoietin Products Dominate the Anti-anaemics Market
- 6.3 Aranesp Dominates the Anti-anaemics Market
- 6.4 Erythropoietin Products
- 6.5 Aranesp Dominates the Erythropoietin Products Market
- 6.6 Aranesp
- 6.6.1 Fears over Erythropoietin Products Overuse
- 6.6.2 Scope for Expansion of Aranesp' s Indications
- 6.6.3 Aranesp' s Edge over Competitors
- 6.6.4 Other Competitiors of Aranesp
- 6.6.5 Entry of Erythropoietin Biosimilars in Europe
- 6.7 Erypo
- 6.7.1 Generic versions of Erypo
- 6.8 Epogen
- 6.9 NeoRecormon
- 6.10 Espo
- 6.11 Iron Replacement Therapy
- 6.12 Drugs with Revenues less than $300m Dominate the Iron Replacement
Therapy Market
- 6.13 Venofer
- 6.14 Other Anti-Anaemics
Chapter 7: Clotting Factors Market
- 7.1 Market Analysis
- 7.2 Novoseven' s Change in Market Share
- 7.3 NovoSeven
Chapter 8: Forces Affecting the Blood Diseases Treatments Market
- 8.1 SWOT Analysis of the Blood Diseases Treatments Market
- 8.2 Market Drivers
- 8.3 Market Restraints
- 8.4 Plavix and Parallel Trade
- 8.5 Strong developmental Pipeline for Drugs on Parr with Lovenox
- 8.6 Ongoing Fears Over the use of Erythropoietin Products in Cancer
Patients
- 8.7 FDA Approves New Haemophilia Treatment
Chapter 9: Geographical Breakdown of the Blood Diseases Treatments Market
- 9.1 The US Holds over 50% Market Share of the Blood Diseases Treatments
Market
- 9.2 Increasing Market Share of Developing Countries at the Cost of
Developed Countries
Chapter 10: Pipeline Products
- 10.1 Anti-thrombotics in the Pipeline
- 10.2 Anti-Anaemics in the Pipeline
- 10.3 Clotting Factors in the Pipeline
- 10.4 Other Blood Diseases Treatments in the Pipeline
Chapter 11: Conclusion
- 11.1 Blood Diseases and Treatments
- 11.2 Blood Diseases Treatments World Market
- 11.3 Blood Diseases Treatments Market Segments
- 11.4 Issues and Opportunities
- 11.5 Products in Development
- 11.6 Geographical Breakdown of the Market
- 11.7 Afterword
List of Tables
- Table 4.1: Forecasts for Blood Diseases Treatments, 2006-2013
- Table 4.2: Forecasts for Blood Diseases Treatments 2018 and 2023
- Table 4.3: Top Ten Products in the Blood Diseases Treatment World Market
2006
- Table 5.1: Antithrombotics Market Forecast, 2006-2013
- Table 5.2: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
- Table 5.3: Forecasts for Platelet Aggregation Inhibitors, 2018 and 2023
- Table 5.4: Injectable Anticoagulants Market Forecast, 2006-2013
- Table 5.5: Injectable Anticoagulants Market Forecast, 2018 and 2023
- Table 6.1: Anti-anaemics Market Forecast, 2006-2013
- Table 6.2: Anti-anaemics Market Forecast, 2018 and 2023
- Table 6.3: Forecasts for Erythropoietin Products, 2006-2013
- Table 6.4: Forecasts for Erythropoietin Products, 2018 and 2023
- Table 6.5: Forecasts for Iron Replacement Therapy, 2006-2013
- Table 6.6: Forecasts for Iron Replacement Therapy, 2018 and 2023
- Table 7.1: Forecasts for Clotting Factors, 2006-2013
- Table 7.2: Forecasts for Clotting Factors, 2018 and 2023
- Table 8.1: A SWOT Chart for the Blood Diseases Treatments Market, 2006-2013
- Table 9.1: Revenue and Market Share of the Leading Pharmaceutical Markets,
2006 and 2013
- Table 10.1: Platelet Aggregation Inhibitors in Development, 2008
- Table 10.2: Injectable Anticoagulants in Development, 2008
- Table 10.3: Other Antithrombotics in Development, 2008
- Table 10.4: Erythropoietin Products in Development, 2008
- Table 10.5: Other Anti-anaemics in Development, 2008
- Table 10.6: Clotting Factors in Development, 2008
- Table 10.7: Other Blood Diseases Treatments in Development, 2008
- Table 11.1: Forecasts for Blood Diseases Treatments, 2006-2013
List of Figures
- Figure 4.1: Forecasts for Blood Diseases Treatments by Market Segment,
2006-2013
- Figure 4.2: Blood Diseases Treatments World Market Forecast, 2006-2013
- Figure 4.3: Blood Diseases Treatments Market Share, 2006
- Figure 4.4: Blood Diseases Treatments Market Share, 2013
- Figure 4.5: Changes in Market Share of the Market Segments
- Figure 4.6: Market Share of the Main Drugs, 2006
- Figure 4.7: Market Share of the Main Drugs, 2013
- Figure 4.8: Changes in revenue from 2006 to 2013 by Market Segment
- Figure 5.1: Antithrombotics Market Forecast, 2006-2013
- Figure 5.2: Antithrombotics Market Share, 2006
- Figure 5.3: Antithrombotics Market Share, 2013
- Figure 5.4: Market Share of the Main Antithrombotics, 2006
- Figure 5.5: Market Share of the Main Antithrombotics, 2013
- Figure 5.6: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
- Figure 5.7: Platelet Aggregation Inhibitors Market Forecast, 2006-2013
- Figure 5.8: Market Share of Platelet Aggregation Inhibitors, 2006
- Figure 5.9: Market Share of Platelet Aggregation Inhibitors, 2013
- Figure 5.10: Plavix Forecast, 2006-2013
- Figure 5.11: Clopidogrel Aptx Forecast, 2006-2013
- Figure 5.12: Pletaal Forecast, 2006-2013
- Figure 5.13: Integrilin Forecast, 2006-2013
- Figure 5.14: Forecasts for Injectable Anticoagulants, 2006-2013
- Figure 5.15: Injectable Anticoagulants Market Forecast, 2006-2013
- Figure 5.16: Injectable Anticoagulants Market Share, 2006
- Figure 5.17: Injectable Anticoagulants Market Share, 2013
- Figure 5.18: Lovenox Forecast, 2006-2013
- Figure 5.19: Fraxiparine Forecast, 2006-2013
- Figure 5.20: Fragmin Forecast, 2006-2013
- Figure 6.1: Anti-anaemics Market Forecast, 2006-2013
- Figure 6.2: Anti-anaemics Market Share, 2006-2013
- Figure 6.3: Anti-anaemics Market Share, 2006-2013
- Figure 6.4: Market Share of the Main Anti-anaemics, 2006
- Figure 6.5: Market Share of the Main Anti-anaemics, 2013
- Figure 6.6: Forecasts for Erythropoietin Products, 2006-2013
- Figure 6.7: Erythropoietin Products Market Forecast, 2006-2013
- Figure 6.8: Erythropoietin Products Market Share, 2006
- Figure 6.9: Erythropoietin Products Market Share, 2013
- Figure 6.10: Aranesp Forecast, 2006-2013
- Figure 6.11: Erypo Forecast, 2006-2013
- Figure 6.12: Epogen Forecast, 2006-2013
- Figure 6.13: NeoRecormon Forecast, 2006-2013
- Figure 6.14: Espo Forecast, 2006-2013
- Figure 6.15: Forecasts for Iron Replacement Therapy, 2006-2013
- Figure 6.16: Iron Replacement Therapy Market Forecast, 2006-2013
- Figure 6.17: Iron Replacement Therapy, 2006
- Figure 6.18: Iron Replacement Therapy Market Share 2013
- Figure 6.19: Venofer Forecast, 2006-2013
- Figure 7.1: Forecasts for Clotting Factors, 2006-2013
- Figure 7.2: Clotting Factors Market Forecast, 2006-2013
- Figure 7.3: Clotting Factors Market Share, 2006
- Figure 7.4: Clotting Factors Market Share, 2013
- Figure 7.5: NovoSeven Forecast, 2006-2013
- Figure 9.1: Revenue of the Leading Pharmaceutical Markets, 2006 and 2013
- Figure 9.2: Market Share of the Leading Pharmaceutical Markets, 2006 and
2013
- Figure 11.1: Blood Diseases Treatments World Market Forecast, 2006-2013
- Figure 11.2: Market Share of the Main Drugs, 2006
- Figure 11.3: Market Share of the Main Drugs, 2013
- Figure 11.4: Changes in revenue from 2006 to 2013 by Market Segment
- Figure 11.5: Forecasts for Blood Diseases Treatments by Market Segment,
2006-2013
- Figure 11.6: Market Share of the Leading Pharmaceutical Markets, 2006 and
2013
Organisations Mentioned in this Report
- Advancell
- Affymax
- Akzo Nobel
- AMAG
- Amgen
- Apotex
- Artisan
- Asahi Kasei
- AstraZeneca
- Barcelona University
- Barr
- Baxter International
- Bayer
- Berlex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cogentus
- Daiichi Sankyo
- Eli Lilly
- Emisphere
- Flamel Technologies
- Fuso
- GlaxoSmithKline
- Green Cross Corporation
- Hexal
- Hospira
- Human Genome Sciences
- JCR Pharmaceuticals
- Johnson & Johnson
- Kissei
- Ligand
- Lundbeck
- Medicines Company
- MedImmune
- Menarini
- National Cancer Institute
- National Institutes of Health
- Nektar
- Novartis
- Novo Nordisk
- Nuvelo
- Ono
- Ormont
- Ortho-McNeil
- Otsuka
- Ovation Pharmaceuticals
- PAION
- PeriCor
- Pfizer
- Protherics
- RHEI
- Roche
- sanofi-aventis
- Schering-Plough
- Servier
- Snow Brand Milk Products
- Stada
- Takeda
- Taro
- Torii
- Ube
- Watson
- Wyeth
|
